Kadimastem Ltd.
Clinical-stage cell therapy company developing treatments for ALS and diabetes.
KDST | TA
Overview
Corporate Details
- ISIN(s):
- IL0011284614
- LEI:
- Country:
- Israel
- Address:
- Pinchas Sapir 3, Weizmann Science Park, 7414003 Nes-Ziona
- Website:
- https://www.kadimastem.com/
Description
Kadimastem is a clinical-stage cell therapy company that develops and manufactures "off-the-shelf" allogeneic cell products. The company utilizes a proprietary technology platform to differentiate human pluripotent stem cells into functional cells for treating diseases. Its lead clinical program, AstroRx®, is an astrocyte cell therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS). Kadimastem is also advancing a preclinical program for Type 1 Diabetes with IsletRx, a product consisting of stem cell-derived pancreatic islet cells intended to restore the body's ability to produce and regulate insulin. The company's focus is on creating regenerative medicine solutions for conditions with high unmet medical needs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-29 11:27 |
Delisting of Securities from Trade on the Tel Aviv Stock Exchange on October 31…
|
English | 104.0 KB | ||
| 2024-05-28 11:41 |
Company Presentation
|
English | 4.4 MB | ||
| 2024-05-28 11:41 |
Company Presentation
|
Russian | 42.5 KB | ||
| 2024-02-12 13:47 |
Excellence Investments Management and Securities will cease to operate as a mar…
|
Hebrew (modern) | 122.7 KB | ||
| 2022-12-13 16:05 |
Rights Offering and Identifying Details for New Security-KADIMASTEM R4
|
Hebrew (modern) | 177.9 KB | ||
| 2022-08-09 13:00 |
Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment
|
English | 12.0 KB | ||
| 2022-06-08 13:00 |
Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement Towards …
|
English | 12.1 KB | ||
| 2022-05-30 15:10 |
Kadimastem Awarded Patent in Japan for AstroRx For ALS and Drug Screening
|
English | 10.6 KB | ||
| 2022-05-18 13:00 |
Kadimastem Expands R&D Program to Include Multiple Sclerosis
|
English | 9.5 KB | ||
| 2022-03-03 14:05 |
Kadimastem Receives Grant for a Total Budget of NIS 10 Million ($3.1 million) f…
|
English | 10.4 KB | ||
| 2021-12-13 13:00 |
Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel I…
|
English | 10.6 KB | ||
| 2021-10-26 07:49 |
Kadimastem Raises $5 million In Private Placement
|
English | 10.5 KB | ||
| 2021-10-25 14:09 |
Kadimastem Raises NIS 16.1 million ($5 million) In Private Placement
|
English | 10.5 KB | ||
| 2021-10-12 15:55 |
Kadimastem Holds Successful Preliminary Meeting with the FDA (INTERACT)
Regar…
|
English | 9.5 KB | ||
| 2021-05-02 19:15 |
Company Presentation May 2021
|
English | 3.0 MB |
Automate Your Workflow. Get a real-time feed of all Kadimastem Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Kadimastem Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Kadimastem Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
